Finn Chelsea T, Vedolin Leonardo, Schwartz Ida V, Giugliani Roberto, Haws Charlotte A, Prescot Andrew P, Renshaw Perry F
Brain Imaging Center, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.
Acta Paediatr. 2008 Apr;97(457):61-8. doi: 10.1111/j.1651-2227.2008.00646.x.
Hunter syndrome is a rare genetic lysosomal storage disease that is caused by a deficiency, or absence, of iduronate-2-sulphatase, an enzyme needed to break down specific glycosaminoglycans (GAGs). As a result, GAGs build up in various tissues throughout the body leading to adverse neurological and non-neurological effects. This literature review focuses on the neurological findings. Although few magnetic resonance imaging studies have been conducted, those done have shown that patients with Hunter syndrome generally exhibit brain atrophy, enlarged periventricular spaces and ventriculomegaly. Similar findings have been reported in other mucopolysaccharide disorders. Enzyme replacement therapy is a novel treatment which has had success in treating peripheral disease in mice and humans.
Future studies should focus on how structural and chemical signatures in the brain of Hunter patients are altered before and after enzyme replacement therapy, and how those alterations correlate with clinical outcome.
亨特综合征是一种罕见的遗传性溶酶体贮积病,由艾杜糖醛酸-2-硫酸酯酶缺乏或缺失引起,该酶是分解特定糖胺聚糖(GAGs)所需的一种酶。结果,GAGs在全身各种组织中蓄积,导致不良的神经和非神经影响。这篇文献综述聚焦于神经学发现。尽管进行的磁共振成像研究很少,但已开展的研究表明,亨特综合征患者通常表现出脑萎缩、脑室周围间隙增宽和脑室扩大。在其他黏多糖病中也报告了类似的发现。酶替代疗法是一种新型治疗方法,已成功用于治疗小鼠和人类的外周疾病。
未来的研究应聚焦于酶替代疗法前后亨特综合征患者大脑中的结构和化学特征是如何改变的,以及这些改变与临床结果如何相关。